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We are grateful to the editors of Genome Medicine, who have
rather incautiously invited us to write a monthly commentary
on the exciting events that have occurred in this burgeoning
field. We have decided to write the column together because
one of us (DGN) is a clinical investigator and the other (SHO)
is a basic geneticist and developmental biologist. Together,
we believe we can do justice to the field and eschew cant. We
begin with a discussion of the controversial role of genome-
wide association studies in clinical medicine.
The development of practical approaches to DNA sequen-
cing in the 1990s produced a remarkable scientific challenge
- a proposal to establish the complete (or near complete)
sequence of the human genome. Although most members of
the scientific community and the media hailed the 2001
announcement of the project’s initial success [1,2] as a huge
intellectual and technical breakthrough, there were other
voices [3]. One of us (SHO) was a member of the original US
National Research Council panel that evaluated the
proposal. The panel was initially highly skeptical but ended
its deliberations with unbridled enthusiasm. Some leading
scientists grumbled that the genome project, as it was called,
was a quagmire and a money sump that had drained funds
from individual investigators and provided a jumble of DNA
bases the sequences of which would shed very little light on
the human condition. The naysayers particularly empha-
sized their doubts that any medical benefit would be derived
from most of the data. Indeed, when most of the human
DNA sequence data had been collected, the laboratories that
had accomplished the feat began to use their considerable
resources to sequence the DNA of one animal species after
another [4,5], with the questionable assumption that know-
ledge of DNA evolution would be useful and not a mere intel-
lectual and technical exercise. Doubters began to wonder
whether a large proportion of the biomedical research
budget would be wasted in an effort to keep sequencing
machines humming. The doubts were, in fact, quite loud in
some quarters, despite the obvious fact that the project has
provided investigators with ready access to all genes and
facilitated positional cloning (see below).
Responding to the criticism, and always ebulliently opti-
mistic, Francis Collins, the guiding spirit of the public effort
to sequence the human genome, simply changed the subject.
He proposed the human HapMap project [6] to replace
laborious and relatively crude restriction enzyme maps. Now
the National Institutes of Health was to finance a study of all
or most of the common variations, rather than just the bases,
in the human genome. Single nucleotide polymorphisms
(SNPs) were to become the lingua franca of medical genetics.
The HapMap project brought forth a bonanza for companies
such as Affymetrix and Illumina, as common SNP detection
moved into a broad base of laboratories and became a
cottage industry.
The obvious potential application of the HapMap project to
medicine lay in disease gene detection. This approach was
initiated by YW Kan, who had shown that the sickle cell
mutation in the first exon of the β globin gene could be
predicted from a restriction enzyme polymorphism well
downstream from the gene itself [7]. Kan’s findings were
based on David Botstein’s proposal to use restriction enzymes
as a tool for linkage mapping in humans [8]. Disease gene
detection was then dramatically advanced by Louis Kunkel,
SHO and their associates, who used what they termed ‘reverse
genetics’ to detect a common muscular dystrophy gene and
the most frequent chronic granulomatous disease gene
[9,10]. They firmly established that disease genes could be
defined by direct analysis of DNA without reliance on the
availability of the offending protein. Others began to use a
candidate gene approach. For example, if we did not already
know the mutation that causes sickle cell anemia, it would berational to probe the α and β globin genes to find it because
the disease is obviously due to a mutation in hemoglobin A.
But sickle cell disease is a monogenic disorder, a perfect
candidate for a candidate gene approach. What about the
polygenic disorders such as obesity and diabetes? There could
be 20 or more genes that interact to produce those syn-
dromes. How can they be found - and how valuable would it
be to find them?
Enter the HapMap project, carrying a huge assumption -
that the disease genes that cause such common illnesses as
diabetes and obesity have not been deleted by natural
selection because such disorders so often occur after pro-
creation has been achieved. Surely the sickle cell gene would
have disappeared if it had not offered partial protection from
the ravages of infantile falciparum malaria. So, the argument
continued, the genes that contribute to obesity and diabetes
could probably be detected by the association of the diseases
with particular common SNPs.
Before one launches into a critique of genome-wide associa-
tion studies, it is important to recognize that all of medicine
is, as emphasized by Jerome Groopman, practiced by asso-
ciation [11]. The sacrosanct history and physical examination
is almost totally based on association. When one reads the
opening sentence of a patient’s chart such as “This six year
old African American male enters the hospital with a chief
complaint of chest pain”, several associations leap to the
fore. He is only six. We do not associate coronary artery
disease with that age. He is African American. We associate
that race with sickle cell disease. He has chest pain. We asso-
ciate that symptom with lung disease. We already wonder
whether he has sickle cell disease and concomitant pneu-
monia. Even the physical examination is performed by asso-
ciation. We look for a tower skull and prominent maxillae
because they are associated with sickle cell disease. We listen
to breath sounds and associate each different sound with a
unique pathology. Now, we could be entirely wrong. He
might be a child with a genetic defect in the coagulation
system who has had a pulmonary embolism. Reliance on
association is clearly dangerous, but without association, the
practice of medicine is crippled. Great clinicians such as the
late Samuel A Levine, one of the fathers of clinical cardiology,
associated large ears and light-colored hair with pernicious
anemia. We don’t know how many normal serum vitamin
B12s DGN measured before he gave up on that association.
Levine went to his grave convinced of its veracity.
The results of genome-wide association studies, in which
common and complex diseases such as obesity and diabetes
are associated with common SNPs, have been controversial
for five main reasons: first, because the assumption that
such SNPs actually exist has not been accepted in many
quarters [12]; second, because, as Walter Bodmer has
recently emphasized [13], much more powerful and histori-
cally established associations, such as the association of
stomach ulcer and cancer with blood group A, have never
been pathophysiologically explained; third, because the
studies as currently constituted can detect only common
variants and not rare ones; fourth, because the current
studies have explained only a small proportion of the herita-
bility of common multigenic diseases; and finally, because it
is not at all clear that any useful therapy can emerge from
the associations. Those who pursue the associations argue
that we can determine the risk of such diseases and ward
them off. But the arcane statistics used to establish the
associations give rise to relative risks of such low order that
it would seem foolhardy to use the weak data in a burst of
what is called personalized medicine. Many of the studies
are underpowered; still more are not reproducible. It would
seem just as rational to advise men with long ears and light-
colored hair to inject themselves with vitamin B12.
Then there is the growing use of genome-wide association
studies to determine clinically important aspects of pharma-
cogenetics. There are certainly genetic bases for drug
sensitivity or resistance; the relationship of warfarin sensi-
tivity to cytochrome p450 polymorphism is an example [14].
But will widespread adoption of SNP analysis of two such
genes really contribute to the management of warfarin
therapy? There are many other acquired causes of warfarin
sensitivity or resistance. Although the test has gained Food
and Drug Administration approval, the jury is out on its
utility. It certainly increases the costs of treatment: that’s all
we know right now.
More problematic applications of genome-wide association
studies can be found in attempts to wander down the genome
with gun and camera and relate common SNPs to clinical
severity. Sickle cell disease is a case in point [15]. We know
that there are globin and non-globin genes that modify the
severity of sickle cell disease. The level of fetal hemoglobin is
a massive modifier. Not surprisingly, the relationship of red
cell membrane area to volume is a modifier because sickle red
cells, like normal cells, must squeeze through tiny apertures.
Therefore, concomitant α-thalassemia is a modifier. The red
cell water content is a critical modifier because sickling is
closely related to hemoglobin concentration. These are
hugely productive areas to investigate that would surely lead
to better treatment. To spend valuable research dollars
wandering around the genome to find ‘modifiers’ with a 1% or
2% effect seems ridiculous on the surface. There must be
some research priorities. Fads such as genome-wide associa-
tion studies do have an important role in certain circum-
stances when modifiers are unknown. But in sickle cell
disease the important modifiers are already known. Let’s use
our increasingly limited ammunition to go after the obvious
opportunities.
Ours is perhaps a dour view. But we are seasoned hands who
have seen many biomedical fads appear, take the front of the
stage and then return to the wings as other actors enter from
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after the obvious and the doable. But, despite our doubts, we
remain hopeful that useful candidate genes and genetic
pathways are likely to emerge from genome-wide association
studies if the studies are performed under stringent condi-
tions, are sufficiently powered and are thoroughly repro-
duced [16,17]. Indeed, one of us (SHO) has recently used
data from genome-wide association studies performed by
others to explore genes that might modify fetal hemoglobin
expression in the hemoglobinopathies [18]. So there is surely
something to be gained from this new approach, but we need
to keep it in perspective and always focus most of our
research resources on experiments that, in the end, are most
likely to contribute to biomedical science and patient care,
now and in the future.
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